ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

Abstract Background First-episode psychosis (FEP) may lead to a progressive, potentially disabling and lifelong chronic illness; however, evidence suggests that the illness course can be improved if appropriate treatments are given at the early stages. Nonetheless, the efficacy of antipsychotic medi...

Full description

Bibliographic Details
Main Authors: S. M. Cotton, M. Berk, A. Watson, S. Wood, K. Allott, C. F. Bartholomeusz, C. C. Bortolasci, K. Walder, B. O’Donoghue, O. M. Dean, A. Chanen, G. P. Amminger, P. D. McGorry, A. Burnside, J. Uren, A. Ratheesh, S. Dodd
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Trials
Subjects:
First-episode psychosis
Psychotic disorders
Neuroprotective agents
Treatment
Outcome
N-acetylcysteine
Online Access:https://doi.org/10.1186/s13063-019-3786-5

Internet

https://doi.org/10.1186/s13063-019-3786-5

Similar Items